Introduction {#S1}
============

Parasites of the genus *Babesia* are prevalent apicomplexan pathogens transmitted by ticks and infect many mammalian and avian species ([@B45]). Human babesiosis is primarily caused by the parasite *Babesia microti*, with most people being infected by ticks and some by blood transfusion ([@B12]; [@B16]; [@B47]). The infection is characterized by fever and hemolytic anemia and can result in death in severe cases from complications, such as heart failure, respiratory distress, and pulmonary edema ([@B33]). Due to the increasing number of people infected with *Babesia*, *B. microti*-related infection has been classified as a nationally notifiable disease since 2011 by the Center for Disease Control (United States) ([@B15]). Babesiosis is usually treated with atovaquone and azithromycin, but resistance to these drugs has been reported ([@B21]; [@B44]; [@B39]). Therefore, it is very urgent to develop new anti-*Babesia* drugs.

Apicomplexan parasites contain a vestigial plastid called the apicoplast ([@B26]), which plays an important role in the biosynthesis of isoprenoid precursors, fatty acids, and part of the heme ([@B32]). However, the apicoplast of *Babesia* is only found in isoprenoid biosynthesis ([@B6]; [@B38]). Apicomplexan parasites utilize the methylerythritol 4-phosphate (MEP) pathway to get isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) ([@B18]), which are the basic units of synthetic isoprenoids and essential for parasite growth ([@B10]).

Isoprenoids comprise a large family and have an important function in membrane structure, cellular respiration, and cell signaling ([@B10]). IPP in living organisms can be synthesized by two pathways \[mevalonate (MVA) pathway and MEP pathway\] ([@B29]). Humans use the MVA pathway to synthesize IPP from acetyl-CoA ([@B9]). However, there is no MVA pathway in the genus of *Apicomplexa*, which thus synthesizes IPP by the MEP pathway ([@B8]). The MEP pathway was first reported to be present in *Plasmodium falciparum* in 1999 ([@B19]). With the deepening of research, the MEP pathway was found to be crucial for parasites ([@B8]). For instance, the deoxyxylose-5-phosphate reductoisomerase (DXR) of *P. falciparum* was shown to contribute to the erythrocyte stage, and inhibiting the DXR activity reduced the growth and the development of the parasites ([@B30]; [@B48]). Additionally, by knocking out the DXR genes of *Toxoplasma gondii*, the parasites were found unable to survive, proving the essentiality of the MEP pathway for their survival ([@B28]).

The first dedicated step in MEP isoprenoid biosynthesis is accomplished by the bifunctional enzyme DXR ([@B18]). DXR is competitively inhibited *in vitro* by the antibiotic fosmidomycin ([@B20]; [@B37]). Fosmidomycin has been shown to be a clinical prospect for antimalarial drugs due to its inhibition on the recombinant *Plasmodium* DXR to kill *Plasmodium*, and the current clinical trial of malaria treatment with clindamycin is in phase II ([@B31]). *Babesia* and *Plasmodium* have many similarities, and they both live in red blood cells (RBCs). In this study, we have found that *B. microti* DXR (BmDXR) has conserved binding sites of fosmidomycin (FSM), and FSM can inhibit the growth of *B. microti in vitro*, suggesting its potential as a new anti-*Babesia* drug.

Materials and Methods {#S2}
=====================

Parasites {#S2.SS1}
---------

A *B. microti* strain ATCC PRA-99TM^®^ ([@B36]) was obtained from the National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention (Shanghai, China), and maintained in our laboratory (State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, China). The parasites were isolated at parasitemia of 30--40% as determined by Giemsa staining of thin blood smears.

RNA Extraction and cDNA Synthesis {#S2.SS2}
---------------------------------

Total RNA was extracted from infected blood by using the TRIZOL reagent (Invitrogen, Shanghai, China) and treated with RNase-free DNase I (TaKaRa, Dalian, China). RNA concentration was measured by NanoDrop 2000 (Thermo, China). The cDNA was prepared from 1 μg of the total RNA using a PrimeScript^TM^ RT reagent kit with gDNA eraser (TaKaRa, Dalian, China).

Cloning of the BmDXR Gene {#S2.SS3}
-------------------------

Primer pairs of BmDXR were designed based on the sequences of the *B. microti* strain R1: BmDXR-F (5'-ATGACAAATTATTT AAAACTC-3') and BmDXR-R (5'-TTAACACTTAATTTTTTT TGC-3'). Complete sequences of the BmDXR were amplified by PCR from cDNA separately. The PCR reaction was performed at 95°C for 5 min, followed by 35 cycles of 95°C for 30 s, 47°C for 30 s, 72°C for 1 min 30 s, and finally at 72°C for 10 min. The PCR products were purified and ligated into the cloning vector pEASY-Blunt (Trans, Beijing, China). Three positive colonies of each gene were sent for sequencing analysis by Invitrogen (Shanghai, China).

Sequence Analysis {#S2.SS4}
-----------------

The amino acid sequence of BmDXR was aligned with the selected amino acid sequences from other organisms by MAFFT online^[1](#footnote1){ref-type="fn"}^, then edited by BioEdit v7.25, and phylogenetically analyzed by using the Maximum Likelihood method in MEGA 7 ([@B22]). The structure of BmDXR was predicted by SWISS-MODEL^[2](#footnote2){ref-type="fn"}^ ([@B13]; [@B4]; [@B42]). The 3D structure of BmDXR was virtually docked with FSM through Molecular Operating Environment (MOE) version 2014.09 (Chemical Computing Group).

### *B. microti* Short-Term *in vitro* Cultivation {#S2.SS4.SSS1}

To cultivate *B. microti in vitro*, infected RBCs and healthy mouse RBCs were collected in tubes containing EDTA-2K solution (solution/RBCs = 1:9; 10% EDTA-2K), followed by centrifugation to pellet the cells at 1,000 *g* for 10 min at room temperature), two washes in PSG solution, resuspension of RBCs in the same volume of PSG + G solution, and storage at 4°C until use. The infected RBCs were diluted with healthy RBCs to 3%, followed by cultivation in the presence of HL-1 supplemented with 10 μg/mg AlbuMax I (Gibco Life Technologies), 1% HB101 (Irvine Scientific, Shanghai, China), 200 μM L-glutamine (ATLANTA Biologicals, Shanghai, China), 2% antibiotic/antimycotic 100 × (Corning, Shanghai, China), and 20% fetal bovine serum at 37°C in a microaerophilous stationary phase (5% CO~2~, 2% O~2~, and 93% N~2~) ([@B1]).

### Fosmidomycin Treatment and Rescue Assay {#S2.SS4.SSS2}

Drug stock solutions of FSM (Sigma-Aldrich, Shanghai, Chain) and diminazene aceturate (DA) (Sigma-Aldrich, Shanghai, Chain) were prepared in sterile water. Geranylgeraniol (Sigma-Aldrich, Shanghai, Chain) stocks were prepared in 100% ethanol. Isopentenyl pyrophosphate triammonium salt solution (Sigma-Aldrich, Shanghai, Chain) was used directly without any additional treatment. For the growth inhibition assay, *B. microti* cultures (20 μl of RBCs plus 100 μl of culture medium) were grown in 96-well flat-bottomed plates, and the susceptibility of *B. microti in vitro* to FSM was evaluated at concentrations up to 500 μM. The results were further confirmed by the IC50 values calculated using the Käber method. All the experiments were repeated three times.

In the rescue experiments, IPP or geranylgeraniol (GG-ol, alcohol of geranylgeranyl diphosphate) was added to the medium containing different drugs. IPP is one of the products in the MEP pathway ([@B14]), and GG-ol is the alcohol analog of the downstream isoprenoids ([@B46]; [@B18]). DA was used as a positive control, and ethanol was used as a negative control. The group of control is only medium. Each drug test was performed in triplicate.

In order to test the parasitemia, three smears were prepared from each well after 72 h of incubation. After air-drying, thin blood smears were fixed with methanol, followed by staining with Giemsa (Sigma-Aldrich, Shanghai, China), and measuring the parasitemia by microscopy. The data were analyzed using GraphPad Prism 7 (San Diego, CA, United States) by two-way analysis of variance (ANOVA), followed by Tukey's multiple-comparison test. The results are shown as mean ± SD (NS, *P* \> 0.05 not significant at 5%; ^∗^*P* \< 0.05 significant at 5%; ^∗∗^*P* \< 0.01 significant at 1%; and ^∗∗∗^ *P* \< 0.001 significant at 0.1%; error bars represent the standard deviations).

Results {#S3}
=======

Cloning and Characterization of *B. microti* DXR {#S3.SS1}
------------------------------------------------

The open reading frame of BmDXR was cloned from *B. microti* PRA99 cDNA by conventional PCR. The results showed that BmDXR is 1,401 bp in length, encoding 466 amino acids with a predicted size of 51.8 kDa. The sequence was submitted to GenBank, with accession number [MK673989](MK673989). BLASTn indicated that BmDXR PRA99 (MK673989) is identical to that of *B. microti* R1 strain (XP_021338225).

Bioinformatic Analysis {#S3.SS2}
----------------------

The obtained BmDXR sequence was characterized by bioinformatic analysis. SignalP4.1 analysis indicated that BmDXR has a 22-amino-acid signal peptide in N-terminus^[3](#footnote3){ref-type="fn"}^, and a 48-amino-acid transit peptide right after the signal peptide. The amino acid sequence of BmDXR was aligned with the DXR amino acid sequences of other apicomplexan parasites by MAFFT. The results showed that BmDXR has the highest similarity to the DXR sequence of *P. falciparum* (AAD03739) with a percent identity of 41.71%, and the lowest similarity to that of *Mycobacterium tuberculosis* (NP_217386), with a percent identity of 36.59% ([Figure 1A](#F1){ref-type="fig"}).

![Bioinformatics analysis of the amino acid sequence of DXR. **(A)** Multiple alignment of DXR amino acid sequences. Ec, *Escherichia coli* (NP_414715); *Mt*, *Mycobacterium tuberculosis* (NP_217386); *Pf*, *Plasmodium falciparum* (AAD03739); *Bm*, *Babesia microti* (XP_021338225). Black shading indicates a similarity in four or in more than four species; gray shading indicates a similarity in three species. Black pane indicates the reported fosmidomycin binding site. **(B)** Neighbor-joining phylogenetic tree based on DXR amino acid sequences. The organism names and sequence accession numbers are indicated. **(C)** Prediction of the structure of BmDXR by SWISS-MODEL. The 3D structure of BmDXR is virtually docked with FSM through MOE2014.0901, and FSM can form hydrogen bonds with Ser217, Asp216, Cys253, Met281, Ser289, Asn294, and Lys295 of BmDXR.](fcell-08-00247-g001){#F1}

DXR amino acid sequences were characterized by phylogenetic analysis with MEGA6, and *B. microti* was shown to fall in the piroplasma clade in the same category of *Plasmodium*. In contrast, bacteria, plant, algae, and sarcocystis are grouped in the same category ([Figure 1B](#F1){ref-type="fig"}). In the piroplasma clade, *B. microti* is significantly different from the other species, including *B. bigemina*, *B. ovata*, *B. bovis*, *T. equi*, *T. orientalis*, *T. parva*, and *T. annulata.*

The 3D structure of BmDXR was predicted by SWISS-MODEL, and BmDXR is shown as a dimeric structure with a metal ion binding site consisting of amino acids D216, E218, and E298. The 3D structure of BmDXR was virtually docked with FSM using MOE2014.0901. The results showed that FSM can form hydrogen bonds with Ser217, Asp216, Cys253, Met281, Ser289, Asn294, and Lys295 of BmDXR ([Figure 1C](#F1){ref-type="fig"}).

Fosmidomycin Inhibits the Growth of *B. microti in vitro* {#S3.SS3}
---------------------------------------------------------

The effect of FSM on the growth of *B. microti in vitro* was tested by adding different concentrations of FSM into the *in vitro* culture medium at an initial percent parasitized erythrocytes (PPE) of 3%. Parasitemia was counted at 72 h post-treatment by microscopy. The parasitemia of the FSM groups is 4.27 ± 0.28%, 3.60 ± 0.16%, 3.09 ± 0.25%, 2.49 ± 0.33%, 1.67 ± 0.18%, and 1.45 ± 0.45% at the concentration of 5, 50, and 500 nM and 5, 50, and 500 μM, respectively, in contrast to an increase from 3% to 4.83 ± 0.8% for the negative control group (the group without drug) after 72 h of culture. After the 72-h treatment, the parasitemia is significantly lower (*P* \< 0.05) in the 50 nM FSM group than in the negative control group, with a significant difference (*P* \< 0.01) between 5 and 50 or 500 nm FSM groups, but no difference between the 50- and 500-μM FSM groups ([Figure 2](#F2){ref-type="fig"}). The test results indicated that the drug efficacy is dose dependent, and FSM could not completely inhibit the growth of *B. microti* even at a drug concentration as high as 500 μM (inhibition rate of 70%). Compared to the negative control group, FSM exhibited a potential anti-*B. microti* activity at a low micromolar concentration, with an IC50 of 4.63 ± 0.12 μM.

![Parasitemia of different drug concentrations after 72 h of treatment. Evaluation of the susceptibility of *B. microti in vitro* to fosmidomycin at concentrations from 5 to 500 μM. Giemsa staining assay at 72 h after the addition of the drug. PPE, pollen productivity estimate; Ns, not significant (*P* \> 0.05); \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001.](fcell-08-00247-g002){#F2}

IPP and GG-ol Can Rescue *B. microti* Treated by Fosmidomycin {#S3.SS4}
-------------------------------------------------------------

The inhibition of FSM on the growth of *B. mitroti* was investigated through rescue experiments in *B. microti in vitro* cultivation with 200 μM IPP and 5 μM GG-ol added separately into 5 μM FSM and 10 μM DA using the latter as a positive control. The 5 μM FSM and 10 μM DA showed 53.8 and 58.6% inhibition on the growth of the parasites ([Figure 3A](#F3){ref-type="fig"}) in the rescue experiment. The growth in 5 μM FSM could be restored by adding 200 μM IPP or 5 μM GG-ol into culture media as indicated by having no difference (*P* \< 0.001) in the relative growth rate among FSM + IPP, GG-ol, and the control ([Figures 3B,C](#F3){ref-type="fig"}). However, the growth in 10 μM DA could not be rescued by adding IPP or GG-ol, as shown by a significant difference (*P* \< 0.001) in the relative growth rate among DA + IPP, DA + GG-ol, and the control \[ANOVA, F(2, 6) = 259.2, *P* \< 0.0001; ANOVA, F(2, 6) = 65.1, *P* \< 0.0001\] ([Figures 3B,C](#F3){ref-type="fig"}).

![IPP and GGol can rescue *B. microti* treated by fosmidomycin and Giemsa staining assay at 72 h after the addition of the drugs. **(A)** Effect of 5 μM fosmidomycin and 10 μM diminazene aceturate on the growth of *B. microti in vitro*. The group of control is only medium. **(B)** Rescue of *B. microti* by adding isopentenyl pyrophosphate. **(C)** Rescue of *B. microti* by adding geranylgeraniol. \*\*\**P* \< 0.001.](fcell-08-00247-g003){#F3}

Discussion {#S4}
==========

The MEP pathway, an essential route in apicomplexan parasites, plays a vital role in the growth of parasites by synthesizing IPP ([@B18]); however, very few effective inhibitors have been studied. Currently, the MEP inhibitors with lower IC50 for *Plasmodium* are FSM and 1R, 3S MMV008138 ([@B11]). DXR is the second and also a rate-limiting enzyme in the MEP pathway ([@B18]). The inhibitors of DXR enzymes, such as FSM, suppress the synthesis of IPP in the MEP pathway of multiple organisms *in vitro* ([Figure 4](#F4){ref-type="fig"}; [@B19]). It has been reported that FSM can inhibit *B. divergen*, *B. bovis*, and *B. orientalis in vitro* ([@B3]; [@B7]; [@B14]). As shown by the reported *P. falciparum* and *M. tuberculosis* crystal structures of inhibitor-free and FSM-bound complete quaternary complexes of DXR ([@B25]; [@B2]; [@B41]), a large cleft was closed between NADPH-binding and catalytic domains upon inhibitor binding, which means that FSM inhibits DXR activity by competing with DOXP. The FSM binding site is conservative, and BmDXR is similar in structure to PfDXR and EcDXR. We speculate that FSM can inhibit the DXR activity in *B. microti* due to its inhibition on the growth of *B. microti* in *in vitro* culture with an FSM IC50 value of 4.63 ± 0.12 μM, which is higher than that of *B. bovis* and *B. bigemina* (3.87 and 2.4 μM, respectively) ([@B40]). The growth of *B. microti* can be rescued by adding IPP or GG-ol in the culture medium, which agreed with the report that GG-ol can rescue the growth of *B. orientalis* inhibited by FSM ([@B14]). These results further suggest that FSM inhibits *B. microti* growth by suppressing the MEP pathway. It is reported that *B. microti*, an obligate parasite of red blood cells ([@B38]), obtains most of the nutrition materials for parasite survival from host red blood cells, but it cannot obtain IPP from host cells due to the small amount of IPP in RBCs ([@B43]). In this case, FSM may inhibit the growth of *B. microti* by suppressing the synthesis of IPP.

![Schematic of isoprenoid metabolism through the non-mevalonate pathway. The methylerythritol 4-phosphate pathway is a unique route to isoprenoid biosynthesis in apicomplexan, and fosmidomycin is a specific inhibitor to 1-deoxy-D-xylulose 5-phosphate reductoisomerase.](fcell-08-00247-g004){#F4}

FSM can cause the death of *P. falciparum* in the first life cycle ([@B17]), but we failed to observe the death of *B. microti* after 24 h of treatment at 5 μM FSM. According to the results of Giemsa staining ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}), we selected the parasites in the period of merozoites and compared their morphologies. All the merozoites in the control group have an obvious contour and a complete shape, while those treated by FSM have lost their contour and complete shape which, however, can be recovered upon addition of IPP or GG-ol in the medium. This is consistent with the observation in *B. bovis* and *B. bigemina* treated with FSM, with obvious changes in the shape of the parasites ([@B40]). These results indicate that IPP is important for *Babesia* to keep a normal shape. Meanwhile, the merozoites treated by DA present a pointed shape, which could not be restored to a normal shape after adding IPP or GG-ol. These morphologies indicate a milder efficacy of FSM than DA because DA made the merozoites of *B. microti* point-like, while FSM caused the parasite to lose its normal form. FSM-treated *P. falciparum* was shown to reduce protein prenylation, leading to marked defects in food vacuolar morphology and integrity ([@B17]). However, no food vacuole has been reported in *B. microti* ([@B35]), suggesting that the impact of FSM on *B. microti* may be different from its influence mechanism on malaria parasites.

Traditionally, azithromycin + atovaquone was used to treat babesiosis in humans and clindamycin + quinine as a treatment strategy for patients with resistance to atovaquone ([@B39]). Meanwhile, many patients have adverse reactions to chloroquine ([@B21]; [@B34]). Generally, traditional treatments cannot eliminate *B. microti* parasitemia completely, suggesting the high recurrence potential of *B. microti*. Despite being a safe and effective inhibitor, FSM has some limitations to clinical applications. First of all, it is an unmodified compound which is very costly. Secondly, FSM has a poor pharmacokinetics profile with a plasma half-life of 3.5 h ([@B27]); it will need multiple shots for clinic use. This limitation of FSM can be solved by drug modification. For example, FR9008 is a derivative of FSM, which has a better effect on *P. falciparum* than FSM. Currently, it is necessary to improve the ability of FSM in entering cells and extend its half-life for clinical applications. We believe that the limitations of FSM can be overcome by drug modification. For drug development, modified drugs have better clinical results; for example, dihydroartemisinin has a better effect than artemisinin in treating *Plasmodium* ([@B24]). About combination therapy, clindamycin + FSM can play a better effect in the treatment of *Plasmodium* ([@B5]), but clindamycin has less effect to *B. microti in vitro* ([@B23]). Other drugs could be used as combination therapy with FSM if required. Our future work will focus on modifying FSM and the combination therapy of FSM.

Conclusion {#S5}
==========

The MEP pathway is a favorable target for drug development. In this study, it is shown that FSM can inhibit the growth of *B. microti in vitro*, which can be rescued by a medium supplemented with IPP or GG-ol. These results indicate that DXR is a potential drug target for designing anti-*Babesia* drugs and that the DXR function and FSM structure contribute to the design of such drugs.
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###### 

Morphology of merozoites cultured *in vitro* for 72 h. 5 μM FSM and 10 μM DA caused changes in merozoite morphology, and 200 μM IPP or 5 μM GG-ol can restore merozoite morphology treated by FSM.

###### 

Click here for additional data file.

DXR

:   1-deoxy-D-xylulose 5-phosphate reductoisomerase
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